1. Repository of OAI
Ελληνικά   English  

Browsing by Author Florentin, M.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jump to: Α Β Γ Δ Ε Ζ Η Θ Ι Κ Λ Μ Ν Ξ Ο Π Ρ Σ Τ Υ Φ Χ Ψ Ω
or enter first few letters:  
View Option
Showing results 1 to 20 of 31  next >
TitleAuthor(s)Issue date???itemlist.???
Aliskiren, a direct renin inhibitor, in clinical practice: a new approach in the treatment of hypertensionMoutzouri, E.; Florentin, M.; Elisaf, M. S.; Mikhailidis, D. P.; Liberopoulos, E. N.24-Nov-2015-
Anticoagulant drugs: what is new?Kei, A.; Florentin, M.; Elisaf, M. S.; Liberopoulos, E.24-Nov-2015-
Association of Helicobacter pylori infection with cardiovascular disease--is it just a myth?Christodoulou, D. K.; Milionis, H. J.; Pappa, P.; Katsanos, K. H.; Sigounas, D.; Florentin, M.; Elisaf, M. S.; Tsianos, E. V.24-Nov-2015-
Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemiaFlorentin, M.; Liberopoulos, E. N.; Mikhailidis, D. P.; Elisaf, M. S.24-Nov-2015-
Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-gamma activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase ARizos, C. V.; Liberopoulos, E. N.; Tellis, C. C.; Florentin, M.; Elisaf, M. S.; Tselepis, A. D.24-Nov-2015-
Combining Rosuvastatin with Sartans of Different Peroxisome Proliferator-Activated Receptor-gamma Activating Capacity Is Not Associated with Different Changes in Low-Density Lipoprotein Subfractions and Plasma Lipoprotein-Associated Phospholipase A(2)Rizos, C. V.; Liberopoulos, E. N.; Tellis, C. C.; Florentin, M.; Elisaf, M. S.; Tselepis, A. D.24-Nov-2015-
Comparison of hemoglobin A1c and fasting glucose criteria to diagnose diabetes among people with metabolic syndrome and fasting glucose above 100 mg/dL (5.5 mmol/L)Liberopoulos, E. N.; Florentin, M.; Kei, A.; Mountzouri, E.; Agouridis, A.; Elisaf, M. S.24-Nov-2015-
Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortalityLiberopoulos, E. N.; Florentin, M.; Mikhailidis, D. P.; Elisaf, M. S.24-Nov-2015-
Drug combinations for dyslipidemia and obesity treatment in metabolic syndromeFlorentin, M.; Elisaf, M. S.; Mikhailidis, D. P.; Liberopoulos, E. N.24-Nov-2015-
Effect of Non-Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed DyslipidaemiaFlorentin, M.; Tselepis, A. D.; Elisaf, M. S.; Rizos, C. V.; Mikhailidis, D. P.; Liberopoulos, E. N.24-Nov-2015-
Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot studyFlorentin, M.; Liberopoulos, E. N.; Filippatos, T. D.; Kostara, C.; Tselepis, A.; Mikhailidis, D. P.; Elisaf, M.24-Nov-2015-
The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemiaFlorentin, M.; Liberopoulos, E. N.; Moutzouri, E.; Rizos, C. V.; Tselepis, A. D.; Elisaf, M. S.24-Nov-2015-
THE EFFECTS OF COMBINING ROSUVASTATIN WITH SARTANS OF DIFFERENT PPAR gamma ACTIVATING CAPACITY ON LOW-DENSITY LIPOPROTEIN SUBFRACTIONS AND LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A(2)Rizos, C. V.; Liberopoulos, E. N.; Tellis, C. C.; Florentin, M.; Elisaf, M. S.; Tselepis, A. D.24-Nov-2015-
Effects of Rimonabant, as Monotherapy and in Combination With Fenofibrate or Ezetimibe, on Plasma Adipokine Levels: A Pilot StudyFlorentin, M.; Liberopoulos, E. N.; Tellis, C. C.; Derdemezis, C. S.; Elisaf, M.; Tselepis, A.24-Nov-2015-
Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective studyRizos, C. V.; Milionis, H. J.; Kostapanos, M. S.; Florentin, M.; Kostara, C. E.; Elisaf, M. S.; Liberopoulos, E. N.24-Nov-2015-
Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemiaFlorentin, M.; Kostapanos, M. S.; Nakou, E. S.; Elisaf, M. S.; Liberopoulos, E. N.24-Nov-2015-
Emerging options in the treatment of dyslipidemias: a bright future?Florentin, M.; Liberopoulos, E. N.; Mikhailidis, D. P.; Elisaf, M. S.24-Nov-2015-
European Panel on Low Density Lipoprotein (LDL) Subclasses: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL SubclassesMikhailidis, D. P.; Elisaf, M.; Rizzo, M.; Berneis, K.; Griffin, B.; Zambon, A.; Athyros, V. G.; de Graaf, J.; Marz, W.; Parhofer, K. G.; Rini, G. B.; Spinas, G. A.; Tomkin, G. H.; Tselepis, A. D.; Wierzbicki, A. S.; Winkler, K.; Florentin, M.; Liberopoulos, E.24-Nov-2015-
Ezetimibe-associated adverse effects: what the clinician needs to knowFlorentin, M.; Liberopoulos, E. N.; Elisaf, M. S.24-Nov-2015-
Fenofibrate in primary biliary cirrhosis: a pilot studyLiberopoulos, E. N.; Florentin, M.; Elisaf, M. S.; Mikhailidis, D. P.; Tsianos, E.24-Nov-2015-
Showing results 1 to 20 of 31  next >